ABSTRACT Transforming growth factors (TGFs) were purified from serum-free medium conditioned by retrovirus-transformed Fisher rat embryo fibroblasts, mouse 3T3 cells, and two human melanoma cell lines. The purification of each TGF was monitored in a radioreceptor assay based on receptor crossreactivity with mouse submaxillary gland epidermal growth factor (mEGF) and was achieved by gel permeation chromatography of the acid-soluble TGF-containing activity, followed by reverse-phase high-pressure liquid chromatography with sequential use of acetonitrile and I-propanol in the presence of aqueous trifluoroacetic acid. The amino-terminal sequences of rat, mouse, and human TGFs were determined. Extensive sequence homology was found among TGF polypeptides from different species and cell types. (9) and for inducing tyrosine phosphorylation of (10) the EGF receptor and in stimulating the phosphorylation, by A431 human carcinoma and mouse 3Th cell membranes, of a synthetic tyrosine-containing peptide (11).
Polypeptide growth factors that are able to confer the transformed phenotype on normal cells have been termed transforming growth factors (TGFs) (1) . The transformed phenotype is operationally defined (2) by the loss of density-dependent inhibition of cell growth in monolayer culture, overgrowth in monolayer culture, characteristic change in cellular morphology, and acquisition of anchorage-independent growth. TGFs have been classified into two categories on the basis of their biological and physical properties (3) . Each member of the type I TGFs (TGFa) competes with epidermal growth factor (EGF) for binding to the cellular EGF receptor. In contrast, type II TGFs (TGFP) display no measurable binding to EGF receptors but may potentiate the growth-stimulating activity of type I TGFs in semisolid medium (4) . Transformed cells cultured in serumfree medium produce and release growth factors with the ability to confer the transformed phenotype on normal fibroblasts (2) and epithelial cells (5) in vitro. Polypeptides with the properties of a type I TGF have been isolated and partially purified from the conditioned medium of Moloney murine sarcoma virus-transformed mouse 3T3 cells (6) , from retrovirus-transformed rat fibroblasts (7) , and from certain human tumor cells (8) . A low molecular weight human melanoma-derived type I TGF (hTGF) has been purified to apparent homogeneity (9) . Both type I hTGF and mouse submaxillary gland EGF (mEGF) are qualitatively and quantitatively nearly indistinguishable in competing for binding to (9) and for inducing tyrosine phosphorylation of (10) the EGF receptor and in stimulating the phosphorylation, by A431 human carcinoma and mouse 3Th cell membranes, of a synthetic tyrosine-containing peptide (11) .
We describe in this paper the large-scale purification of low molecular weight rat and mouse type I TGFs (rTGF and mTGF) and of hTGF that are produced by Snyder-Theilen feline sarcoma virus-transformed Fisher rat embryo fibroblasts, Moloney murine sarcoma virus-transformed mouse 3T3 cells, and two human melanoma cell lines, respectively. The purification of each TGF was monitored in a radioreceptor assay based on receptor crossreactivity with mEGF. The amino-terminal sequences of the isolated polypeptides are reported. The data clearly define the structural relationship among these functionally indistinguishable type I TGF polypeptides and establish unequivocally a structural relationship to EGF.
MATERIALS AND METHODS Source of TGF. rTGF, mTGF, and hTGF were purified from the serum-free medium conditioned respectively by Fisher rat embryo fibroblasts FRE C110, a subelone of FRE 3A (12), nonproductively transformed by Snyder-Theilen feline sarcoma virus (13) ; by a Moloney murine sarcoma virus-transformed mouse 3T3 cell line, 3B11-IC (14) ; and by two human metastatic melanoma lines, A2058 (8) and A375 (15) . Cells were grown in 2-liter plastic roller bottles containing Dulbecco's modified Eagle's medium supplemented with 10% calf serum and subsequently maintained in serum-free Waymouth's medium as described (2). Serum-free conditioned medium was collected every 24 hr for a 3-day period and clarified by continuous flow centrifugation. The supernatant was concentrated (16) , and this concentrate of conditioned medium was the starting material for the purification of TGFs.
Purification of TGF. rTGF and mTGF were prepared essentially as described (9) The final purification of rTGF, mTGF, and hTGF was achieved by reverse-phase HPLC. The chromatography system has been described (17) . The separations were performed on a ,4Bondapak C18 column (10-gim particle size, 0.39 X 30 cm, Waters Associates). The mobile phase was 0.05% trifluoroacetic acid, and the mobile-phase modifier was acetonitrile containing 0.045% trifluoroacetic acid. The concentration of acetonitrile was increased linearly (0.083%/min) during 2 hr at a flow rate of 1 ml/min at 40'C for elution of peptides. TGF-containing pools were lyophilized and reconstituted in 0.05% trifluoroacetic acid and were rechromatographed on the same column, with 1-propanol containing 0.035% trifluoroacetic acid as the mobile-phase modifier. The 1-propanol concentration was increased linearly (0.05%/min) during 2 hr at a flow rate of 1 ml/ min at 40'C. Pools of fractions comprising the major EGF-competing activity were lyophilized.
Assay for TGF. TGF was quantitated in a radioreceptor assay based on receptor crossreactivity with mEGF. Purified mEGF (18) was labeled with Nal251 (l25I-EGF) by a modification of the chloramine-T method (19) as described (6 (20) of S-carboxamidomethylated rTGF and unmodified mTGF and hTGF were performed with a gas/liquid solid-phase microsequenator (21) . Sequenator fractions were analyzed by reverse-phase HPLC (22) .
Statistical Analyses for Relatedness of the TGF Amino Acid Sequence to Other Proteins. The partial amino acid sequence of rTGF was compared with each known sequence stored in a protein sequence data base (23) using the SEARCH program (24) . Homologies between the rTGF sequence and those of mEGF (25) and human urogastrone (hEGF) (26) were established by using the program ALIGN (27) . The program ALIGN determines a best alignment of two protein sequences (including gaps) by computing the maximum match score using the mutation data matrix (250 PAMs) (28) with a matrix bias parameter and a penalty parameter each set to 6. This score is then compared with the highest possible scores obtained by aligning pairs of 100 random formulations having the same amino acid composition as the two real sequences. The scores of the randomized sequences form a normal distribution for which the mean and standard deviation are calculated. The probability that the score for the real sequences is derived from this normal distribution is then obtained.
RESULTS
Purification of TGF. Purified preparations of a low molecular weight rTGF, mTGF, and hTGF were obtained from the conditioned medium of retrovirus-transformed rat and mouse fibroblasts and two human melanoma cell lines, respectively. The purification was achieved by gel permeation chromatography of the acid-soluble EGF-competing activity on Bio-Gel P-10 in 1 M acetic acid, followed by reverse-phase HPLC on ,uBondapak C18 support with sequential use of a linear gradient of aqueous acetonitrile and 1-propanol containing trifluoroacetic acid. Typical elution patterns of the final purification step of rTGF, mTGF, and hTGF are shown in Fig. 1 . EGF-competing activity copurified with a distinct absorbance peak, indicated with a bar, and was effectively separated from contaminating UV-absorbing material. The major protein peak in rTGF, mTGF, and hTGF preparations was eluted from a gBondapak C18 column under standard conditions between 48 and 55 min.
Gel permeation chromatography on Bio-Gel P-10 provided a separation of the low molecular weight TGFs from larger molecular weight TGFs and reduced the load of protein applied to a pJBondapak C18 column in the following purification step.
The low molecular weight TGFs represented 45-80% of the initial total EGF-competing activity. Reverse-phase HPLC of TGFs on tBondapak C18 support in the following two purification steps was very efficient, each step in a typical preparation giving a recovery range of 80-100%. The final recovery of the low molecular weight TGFs was approximately 70%, based on the maximal total EGF-competing activity detected during the course of the purification. The average yield per liter of conditioned medium of purified rTGF was 90 ng, of mTGF was 50 ng, and of hTGF was 10 ng. This calculation is based on the specific activity determined for isolated TGFs and on the assumption that the EGF-competing activity measured in the radioreceptor assay reflects levels of total large and low molecular weight TGFs only. No immunoreactive mEGF was detected in conditioned medium (2) .
Purity of TGF. The purity of rTGF, mTGF, and hTGF suggested by the chromatographic elution profiles was assessed in the EGF radioreceptor assay and by amino acid sequence analysis. rTGF, mTGF, and hTGF competed with 125I-EGF for the EGF receptor sites on A431 human carcinoma cells and were qualitatively and quantitatively nearly indistinguishable from mEGF. Hence, the final TGF preparations were believed to be highly purified and close to homogeneity. A single amino-terminal sequence was determined by automated Edman degradation for rTGF, mTGF, and hTGF. Any unblocked minor peptide sequence present at >5% could have been detected by the methods used. The homogeneity of hTGF was confirmed in addition by analytical NaDodSO4/polyacrylamide gel electrophoresis. The purified preparation gave one major polypeptide band (9 Fig. 3 . The alignment scores, A, from intercomparisons of rTGF, mEGF, and hEGF are shown in Table 1 . The probabilities of rTGF being so similar by chance to mEGF and hEGF are <10-11. DISCUSSION Type I TGFs were isolated from serum-free medium conditioned by retrovirus-transformed rat and mouse fibroblasts and human melanoma cells. The purification of TGFs was.monitored in a radioreceptor assay developed for mEGF and was achieved by gel permeation chromatography and reverse-phase HPLC with sequential use of mobile-phase modifiers of different solvent polarity in the presence of the same hydrophobic counterion. TGFs could be directly identified in the last purification step by determining the characteristic elution positions of rTGF, mTGF, and hTGF when chromatographed on p.Bondapak C18 support (Fig. 1) and quantitated by integrating peak areas. The recovery of isolated TGFs from conditioned medium was about 70%.
Comparison of the amino-terminal sequences of rTGF, mTGF, and hTGF revealed a high degree of sequence homology. When the sequences were aligned, as shown in Fig.  2 , all of the identified residues in rTGF and mTGF were identical. A comparison of the amino-terminal sequence of rTGF with the amino-terminal sequence of hTGF indicated that hTGF and rTGF differed from each other by at least three amino acid substitutions. The sequence of hTGF differed from that of rTGF by substitution of aspartic acid for lysine in position 7, a conservative substitution of phenylalanine for tyrosine in position 15, and a substitution in position 23, although not positively identified; 23 of 26 amino acid positions, or 88%, are identical. 25 30 35
Alignment of amino-terminal sequences of rTGF, mTGF, and hTGF. Amino acid residues are given in single letter code (29) . Residues in the amino acid sequence of hTGF that differ from those in sequences of rTGF and mTGF are underlined. X, Unidentified residue.
Proc. Natl. Acad. Sci. USA 80,(1983) (25) , and hEGF (26) . Numbers in parentheses denote actual residues compared. Amino acid residues are given in single letter code (29 An interesting feature of the amino-terminal sequence of rTGF is the structural relationship to hEGF and mEGF. A computerassisted alignment (Fig. 3) 
